DeFronzo RA, Davidson JA, del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5–14. https://doi.org/10.1111/j.1463-1326.2011.01511.x.

Article  CAS  PubMed  Google Scholar 

Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139:1384–95. https://doi.org/10.1161/CIRCULATIONAHA.118.037778.

Article  CAS  PubMed  PubMed Central  Google Scholar 

ICS | Overactive Bladder n.d. https://www.ics.org/committees/standardisation/terminologydiscussions/overactivebladder. Accessed 21 June 2024.

Puckrein G, Walker D, Xu L, Congdon P, Gooch K. The prevalence and forecast prevalence of overactive bladder in the Medicare population. Clin Med Insights Urol. 2019;12:1–8. https://doi.org/10.1177/1179561119847464.

Article  Google Scholar 

Qudah S, Abufaraj M, Farah R, Almazeedi A, Ababneh A, Alnabulsi M, et al. The prevalence of overactive bladder and its impact on the quality of life: a cross-sectional study. Arab J Urol. 2024;22:39–47. https://doi.org/10.1080/2090598X.2023.2221403.

Article  PubMed  Google Scholar 

Krepostman N, Kramer H. Lower urinary tract symptoms should be queried when initiating sodium glucose co-transporter 2 inhibitors. Kidney360. 2021;2:751–4. https://doi.org/10.34067/KID.0000472021.

Article  PubMed  PubMed Central  Google Scholar 

Tarcan T, Mangır N, Özgür MÖ, Akbal C. OAB-V8 Aşırı Aktif Mesane Sorgulama Formu Validasyon Çalışması. Üroloji Bülteni 2012:113–6.

Chilelli NC, Bax G, Bonaldo G, Ragazzi E, Iafrate M, Zattoni F, et al. Lower urinary tract symptoms (LUTS) in males with Type 2 Diabetes recently treated with SGLT2 inhibitors—overlooked and overwhelming? A retrospective case series. Endocrine. 2018;59:690–3. https://doi.org/10.1007/s12020-017-1301-x.

Article  CAS  PubMed  Google Scholar 

Tanaka H, Takano K, Iijima H, Kubo H, Maruyama N, Hashimoto T, et al. Factors affecting Canagliflozin-induced transient urine volume increase in patients with Type 2 Diabetes Mellitus. Adv Ther. 2017;34:436–51. https://doi.org/10.1007/s12325-016-0457-8.

Article  CAS  PubMed  Google Scholar 

Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11:563–74. https://doi.org/10.1023/a:1016370925601.

Article  CAS  PubMed  Google Scholar 

Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn. 2005;24:215–25. https://doi.org/10.1002/nau.20110.

Article  PubMed  Google Scholar 

Ozaki AF, Ko DT, Chong A, Fang J, Atzema CL, Austin PC, et al. Prescribing patterns and factors associated with sodium–glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease. CMAJ Open. 2023;11:E494-503. https://doi.org/10.9778/cmajo.20220039.

Article  PubMed  PubMed Central  Google Scholar 

Shikuma J, Ito R, Sasaki-Shima J, Teshima A, Hara K, Takahashi T, et al. Changes in overactive bladder symptoms after SGLT2 inhibitor administration in type 2 diabetes. Pract Diabetes. 2018;35:47–50. https://doi.org/10.1002/pdi.2160.

Article  Google Scholar 

Celenay ST, Secer E, Karaaslan Y, Korkut Z, Kaya DO. Responsiveness, minimal detectable change, and minimal clinically important difference of the Turkish version of the 8-item overactive bladder questionnaire. Int Urogynecol J. 2026. https://doi.org/10.1007/s00192-025-06514-2.

Article  PubMed  Google Scholar 

Lawrence JM, Lukacz ES, Liu ILA, Nager CW, Luber KM. Pelvic floor disorders, diabetes, and obesity in women: findings from the Kaiser Permanente continence associated risk epidemiology study. Diabetes Care. 2007;30:2536–41. https://doi.org/10.2337/dc07-0262.

Article  PubMed  Google Scholar 

Liu RT, Chung MS, Lee WC, Chang SW, Huang ST, Yang KD, et al. Prevalence of overactive bladder and associated risk factors in 1359 patients with type 2 diabetes. Urology. 2011;78:1040–5. https://doi.org/10.1016/j.urology.2011.05.017.

Article  PubMed  Google Scholar 

Kandeel M. The outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2I) on diabetes-associated neuropathy: A systematic review and meta-analysis. Front Pharmacol. 2022;13:1–8. https://doi.org/10.3389/fphar.2022.926717.

Article  CAS  Google Scholar 

Saijo Y, Okada H, Hata S, Nakajima H, Kitagawa N, Okamura T, et al. Reasons for discontinuing treatment with sodium-glucose cotransporter 2 inhibitors in patients with diabetes in real-world settings: The KAMOGAWA-A study. J Clin Med. 2023;12:1–10. https://doi.org/10.3390/jcm12226993.

Article  CAS  Google Scholar 

Custódio JS, Roriz-Filho J, Cavalcanti CAJ, Martins A, Salles JEN. Use of SGLT2 inhibitors in older adults: Scientific evidence and practical aspects. Drugs Aging. 2020;37:399–409. https://doi.org/10.1007/s40266-020-00757-y.

Article  CAS  PubMed  Google Scholar 

Wang X, Yu Q, Michel MC. Editorial: Benign prostatic hyperplasia and overactive bladder: New members of metabolic syndrome. Front Urol. 2023;3:1–3. https://doi.org/10.3389/fruro.2023.1272592.

Article  Google Scholar 

Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: Prevalence and incident rates. Urol Clin North Am. 2016;43:289–97. https://doi.org/10.1016/j.ucl.2016.04.001.

Article  PubMed  Google Scholar 

Yasui A, Lee G, Hirase T, Kaneko T, Kaspers S, Von Eynatten M, et al. Empagliflozin induces transient diuresis without changing long-term overall fluid balance in Japanese patients with type 2 diabetes. Diabetes Ther. 2018;9:863–71. https://doi.org/10.1007/s13300-018-0385-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, et al. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS ONE. 2014;9:1–12. https://doi.org/10.1371/journal.pone.0105638.

Article  Google Scholar 

Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:613–21. https://doi.org/10.1111/dom.12073.

Article  CAS  PubMed  Google Scholar 

Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci. 2019;20:1–13. https://doi.org/10.3390/ijms20030629.

Article  CAS  Google Scholar 

Ishibashi F, Kosaka A, Tavakoli M. Sodium Glucose Cotransporter-2 inhibitor protects against diabetic neuropathy and nephropathy in modestly controlled type 2 diabetes: follow-up study. Front Endocrinol (Lausanne). 2022;13:1–10. https://doi.org/10.3389/fendo.2022.864332.

Article  Google Scholar 

Ito H, Watanabe E, Tanaka M, Matsumoto S, Inoue H, Antoku S, et al. Prevalence and associated factors of overactive bladder in Japanese patients with type 2 diabetes. Geriatr Gerontol Int. 2026;26:1–9. https://doi.org/10.1111/ggi.70312.

Article  Google Scholar 

Roth BJ, Gill BC, Khooblall P, Vallabhaneni S, Bole R, Bajic P. Associations between Sodium-Glucose Co-transporter 2 inhibitors and urologic diseases: implications for lower urinary tract symptoms from a multi-state health system analysis. Urology. 2024;192:119–25. https://doi.org/10.1016/j.urology.2024.06.036.

Article  PubMed  Google Scholar 

Qian Z, Song J, Jones A, Tao B, Xiao B, Labban M, et al. SGLT2 inhibitor and urinary tract infection in men at risk for voiding dysfunction: a VigiBase analysis. Urol Pract. 2025;12:131–7. https://doi.org/10.1097/UPJ.0000000000000698.

Article  PubMed  Google Scholar 

Kawahara T, Toda M, Kanagawa M, Toyama N, Suzuki G, Kawahara C, et al. Differential effects of SGLT-2 inhibitors on liver function and nocturia in patients with type 2 diabetes: a randomized controlled trial. Diabetes Metab Syndr Obes. 2025;18:2611–22. https://doi.org/10.2147/DMSO.S547088.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erdogan BR, Liu G, Arioglu-Inan E, Michel MC. Established and emerging treatments for diabetes-associated lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol. 2022;395:887–906. https://doi.org/10.1007/s00210-022-02249-9.

Article  CAS